Literature DB >> 30793153

A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.

Yan Guo1, Shuren Zhang, Hao Yuan, Dongfan Song, Suxing Jin, Zijian Guo, Xiaoyong Wang.   

Abstract

A PtIV prodrug (PDMA) exhibits great potential for the therapy of metastatic triple-negative breast cancer (TNBC) through a synergistic action of antiangiogensis and antimetastasis.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30793153     DOI： 10.1039/c9dt00335e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN： 1477-9226            Impact factor:   4.390


  2 in total

Review 1.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

Authors:  Nazia Nayeem; Maria Contel
Journal:  Chemistry       Date:  2021-05-05       Impact factor: 5.020

Review 2.  Mechanistic Targets and Nutritionally Relevant Intervention Strategies to Break Obesity-Breast Cancer Links.

Authors:  Ximena M Bustamante-Marin; Jenna L Merlino; Emily Devericks; Meredith S Carson; Stephen D Hursting; Delisha A Stewart
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-17       Impact factor: 6.055
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.